# US 2025/0049954 A1 · Stable compositions of mrna-loaded lipid nanoparticles and processes of making

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0049954 A1
- Document ID: US20250049954A1
- Status: Published application
- Kind: A1
- Application number: 18/910,694
- Filed: 2024-10-09
- Published: 2025-02-13
- Earliest claimed: 2019-07-23
- Applicants: Translate Bio, Inc.
- Inventors: Shrirang KARVE; Frank DEROSA; Michael HEARTLEIN; Natalia VARGAS MONTOYA; Priyal PATEL; Ashish SARODE
- Web page: https://patentgrep.com/patent/US20250049954A1

## CPC

- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61K 9/1075: {Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence)}
- A61K 9/5146: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides}
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61K 48/0041: {the non-active part being polymeric}
- C12N 15/88: using microencapsulation, e.g. using {amphiphile} liposome vesicle
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides an improved compositions and processes for preparing mRNA-loaded lipid nanoparticles (mRNA-LNPs). In some embodiments, the present invention provides mRNA-LNPs with exceptional stability and is particularly useful in cases where LNPs comprising low or no PEG-modified lipids are desired.

## Claims

### Claim 1

A stable composition comprising lipid nanoparticles encapsulating messenger RNA mRNA, wherein the mRNA encodes a protein or a peptide, wherein each of the lipid nanoparticles comprises one or more cationic lipids, one or more non-cationic lipids and less than 0.5% of PEG-modified lipids or PEG, and wherein the lipid nanoparticles encapsulating the mRNA are stable following one or more freeze thaws.

### Claim 2 (depends on 1)

The stable composition of claim 1, wherein each of the lipid nanoparticles comprises one cationic lipid, dioleoylphosphatidylethanolamine (DOPE), and less than about 0.5% of PEG-modified lipids or PEG.

### Claim 3 (depends on 1, 2)

The stable composition of claim 1 or 2, wherein the lipid nanoparticles encapsulating the mRNA maintain an average diameter within 50% of the original average size following one or more freeze thaw cycles.

### Claim 4

The stable composition of any one of the preceding claims, wherein the lipid nanoparticles encapsulating the mRNA maintains an average diameter within 10% of the original average size following one or more freeze thaw cycles.

### Claim 5

The stable composition of any one of the preceding claims, wherein the lipid nanoparticles encapsulating the mRNA maintains an average diameter within 5% of the original average size following one or more freeze thaw cycles.

### Claim 6

The stable composition of any one of the preceding claims, wherein the lipid nanoparticles have an mRNA encapsulation efficiency of between about 50% and 99%.

### Claim 7

The stable composition of any one of the preceding claims, wherein each of the lipid nanoparticles further comprises a cholesterol-based lipid.

### Claim 8

The stable composition of any one of the preceding claims, wherein each of the lipid nanoparticles comprises 0.4% of PEG-modified lipids or less, 0.3% of PEG-modified lipids or less, 0.2% of PEG-modified lipids or less, or 0.1% of PEG-modified lipids or less.

### Claim 9

The stable composition of any one of the preceding claims, wherein each of the lipid nanoparticles is substantially free of PEG-modified lipids.

### Claim 10

The stable composition of any one of the preceding claims, wherein each of the lipid nanoparticles comprises an amphiphilic block copolymer.

### Claim 11 (depends on 10)

The stable composition of claim 10, wherein each of the lipid nanoparticles comprises less than 3% amphiphilic block copolymer, less than 2.5% amphiphilic block copolymer, less than 2% amphiphilic block copolymer, less than 1.5% amphiphilic block copolymer, less than 1% amphiphilic block copolymer, less than 0.5% amphiphilic block copolymer, less than 0.05% amphiphilic block copolymer, or less than 0.01% amphiphilic block copolymer.

### Claim 12 (depends on 11)

The stable composition of claim 11, wherein the composition comprises less than 0.05%, less than 0.04%, less than 0.03%, less than 0.02%, or less than 0.01% amphiphilic block copolymer of the total composition by weight.

### Claim 13 (depends on 12)

The stable composition of claim 12, wherein the composition comprises a residual of amphiphilic block copolymer.

### Claim 14 (depends on 10, 11, 12, 13)

The stable composition of any one of claims 10-13, wherein the amphiphilic block copolymer is a poloxamer.

### Claim 15 (depends on 14)

The stable composition of claim 14, wherein the poloxamer is selected from poloxamer 84, poloxamer 101, poloxamer 105, poloxamer 108, poloxamer 122, poloxamer 123, poloxamer 124, poloxamer 181, poloxamer 182, poloxamer 183, poloxamer 184, poloxamer 185, poloxamer 188, poloxamer 212, poloxamer 215, poloxamer 217, poloxamer 231, poloxamer 234, poloxamer 235, poloxamer 237, poloxamer 238, poloxamer 282, poloxamer 284, poloxamer 288, poloxamer 304, poloxamer 331, poloxamer 333, poloxamer 334, poloxamer 335, poloxamer 338, poloxamer 401, poloxamer 402, poloxamer 403, poloxamer 407 or combination thereof.

### Claim 16

A stable composition comprising lipid nanoparticles encapsulating a messenger RNA (mRNA) that encodes a protein or a peptide, wherein each of the lipid nanoparticles comprises one or more cationic lipids, one or more non-cationic lipids, a poloxamer and is substantially free of PEG-modified lipids or PEG, and wherein the lipid nanoparticles encapsulating the mRNA are stable following one or more freeze thaw cycles.

### Claim 17

A stable composition comprising lipid nanoparticles encapsulating a messenger RNA (mRNA) that encodes a protein or a peptide, wherein each of the lipid nanoparticles comprises one or more cationic lipids, one or more non-cationic lipids, a poloxamer and is substantially free of PEG-modified lipids or PEG, and wherein the lipid nanoparticles encapsulating the mRNA generate low to no anti-PEG antibodies, and/or reduce accelerated blood clearance (ABC).

### Claim 18 (depends on 17)

The stable composition of claim 17, wherein the poloxamer is present in the lipid nanoparticles at an amount of less than 0.1%.

### Claim 19 (depends on 16, 17, 18)

The stable composition of any one of claims 16-18, wherein the poloxamer is present in the lipid nanoparticles at an amount of at less than 0.05%.

### Claim 20 (depends on 16, 17, 18, 19)

The stable composition of any one of claims 16-19, wherein the non-cationic lipid is dioleoylphosphatidylethanolamine (DOPE).

### Claim 21 (depends on 16, 17, 18, 19, 20)

The stable composition of any one of claims 16-20, wherein the lipid nanoparticle maintain an average diameter within 50% of the original average size following one or more freeze thaw cycles.

### Claim 22 (depends on 21)

The stable composition of claim 21, wherein the lipid nanoparticles maintain an average diameter within 10% of the original average size following one or more freeze thaw cycles.

### Claim 23 (depends on 22)

The stable composition of claim 22, wherein the lipid nanoparticles maintain an average diameter within 5% of the original average size following one or more freeze thaw cycles.

### Claim 24 (depends on 16, 17, 18, 19, 20, 21, 22, 23)

The stable composition of any one of claims 16-23, wherein the lipid nanoparticles have an mRNA encapsulation efficiency of between about 50% and 99%.

### Claim 25 (depends on 16, 17, 18, 19, 20, 21, 22, 23, 24)

The stable composition of any one of claims 16-24, wherein each of the lipid nanoparticles further comprises cholesterol-based lipid.

### Claim 26 (depends on 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The stable composition of any one of claims 16-25, wherein each of the lipid nanoparticles does not comprise cholesterol-based lipid.

### Claim 27 (depends on 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The stable composition of any of claims 16-26, wherein each of the lipid nanoparticles is a two-component lipid nanoparticle.

### Claim 28 (depends on 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The stable composition of any one of claims 16-27, wherein the poloxamer has ethylene oxide units from about 10 to about 150.

### Claim 29 (depends on 28)

The stable composition of claim 28, wherein the poloxamer has propylene oxide units from about 10 to about 100.

### Claim 30 (depends on 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The stable composition of any one of claims 16-29, wherein the poloxamer has an average molecular weight of about 4,000 g/mol to about 20,000 g/mol.

### Claim 31 (depends on 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The stable composition of any one of claims 16-30, wherein the poloxamer is selected from poloxamer 84, poloxamer 101, poloxamer 105, poloxamer 108, poloxamer 122, poloxamer 123, poloxamer 124, poloxamer 181, poloxamer 182, poloxamer 183, poloxamer 184, poloxamer 185, poloxamer 188, poloxamer 212, poloxamer 215, poloxamer 217, poloxamer 231, poloxamer 234, poloxamer 235, poloxamer 237, poloxamer 238, poloxamer 282, poloxamer 284, poloxamer 288, poloxamer 304, poloxamer 331, poloxamer 333, poloxamer 334, poloxamer 335, poloxamer 338, poloxamer 401, poloxamer 402, poloxamer 403, poloxamer 407 or combination thereof.

### Claim 32

The stable composition of any one of the preceding claims, wherein the lipid nanoparticles have an average size of less than about 200 nm.

### Claim 33 (depends on 32)

The stable composition of claim 32, wherein the average size is about 150 nm, 140 nm, 130 nm, 120 nm, 110 nm, 100 nm or less.

### Claim 34

The stable composition of any one of the preceding claims, wherein the lipid nanoparticles have a polydispersity index (PDI) of 0.25 or less, 0.2 or less, 0.15 or less, 0.1 or less.

### Claim 35

A method for delivery of messenger RNA (mRNA) for in vivo production of a protein or a peptide, comprising administering to a subject a stable composition according to any one of the preceding claims.

### Claim 36

A method for delivery of messenger RNA (mRNA) for in vivo production of a protein or a peptide, comprising administering to a subject a stable composition according to any one of the preceding claims, wherein the administering the stable composition does not results in anti-PEG antibodies and/or accelerated blood clearance (ABC) in the subject.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

A method of treating a subject having a deficiency in a protein or peptide, comprising administering to a subject in need of treatment a stable composition according to any one of claims 1-33.

### Claim 38 (depends on 35, 36, 37)

The method of any one of claims 35-37, wherein the stable composition is administered by intravenous injection.

### Claim 39 (depends on 35, 36, 37)

The method of any one of claims 35-37, wherein the stable composition is administered by pulmonary delivery.

### Claim 40 (depends on 35, 36, 37)

The method of any one of claims 35-37, wherein the stable composition is administered by intramuscular delivery.

### Claim 41 (depends on 35, 36, 37, 38, 39, 40)

The method of any one of claims 35-40, wherein the administering of the stable composition results in expression of the protein or the peptide encoded by the mRNA for at least about 12, 24, 36, 48, 60, or 72 hours after administration.

### Claim 42

A process of encapsulating messenger RNA (mRNA) in lipid nanoparticles comprising a step of mixing an mRNA solution and a lipid solution in the presence of a poloxamer.

### Claim 43 (depends on 42)

The process of claim 42, wherein the lipid solution comprises one or more cationic lipids, one or more non-cationic lipids and less than 0.5% of PEG-modified lipids or PEG.

### Claim 44 (depends on 42, 43)

The process of claim 42 or 43, wherein the lipid solution comprises pre-formed lipid nanoparticles.

### Claim 45 (depends on 42, 43, 44)

The process of any one of claims 42-44, wherein the mRNA solution and/or the lipid solution are at a pre-determined temperature higher than ambient temperature.

### Claim 46 (depends on 42, 43, 44, 45)

The process of any one of claims 42-45, wherein the poloxamer is first added to the mRNA solution.

### Claim 47 (depends on 42, 43, 44, 45, 46)

The process of any one of claims 42-46, wherein the poloxamer is present in an amount lower than its critical micelle concentration (CMC).

### Claim 48 (depends on 47)

The process of claim 47, wherein the poloxamer is present in an amount about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, or about 50% lower than its CMC.

### Claim 49 (depends on 47)

The process of claim 47, wherein the poloxamer is present in an amount less than about 50% of its CMC.

### Claim 50 (depends on 42, 43, 44, 45, 46, 47, 48, 49)

The process of any one of claims 42-49, wherein the process further comprises a step of removing the poloxamer.

### Claim 51 (depends on 50)

The process of claim 50, wherein the poloxamer is removed by dialysis.

### Claim 52 (depends on 50, 51)

The process of claim 50 or 51, wherein less than about 0.05% poloxamer remains upon removal.

### Claim 53 (depends on 52)

The process of claim 52, wherein less than about 0.01% poloxamer remains upon removal.

### Claim 54 (depends on 52)

The process of claim 52, wherein a residual amount of poloxamer remains upon removal.

### Claim 55 (depends on 50, 51, 52, 53, 54)

The process of any one of claims 50-54, wherein the amount of poloxamer remaining after removal is undetectable.

### Claim 56 (depends on 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55)

The process of any one of claims 42-55, wherein the poloxamer has ethylene oxide units from about 10 to about 150.

### Claim 57 (depends on 56)

The process of claim 56, wherein the poloxamer has propylene oxide units from about 10 to about 100.

### Claim 58 (depends on 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

The process of any one of claims 42-57, wherein the poloxamer has an average molecular weight of about 4,000 g/mol to about 20,000 g/mol.

### Claim 59 (depends on 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58)

The process of any one of claims 42-58, wherein the poloxamer is selected from poloxamer 84, poloxamer 101, poloxamer 105, poloxamer 108, poloxamer 122, poloxamer 123, poloxamer 124, poloxamer 181, poloxamer 182, poloxamer 183, poloxamer 184, poloxamer 185, poloxamer 188, poloxamer 212, poloxamer 215, poloxamer 217, poloxamer 231, poloxamer 234, poloxamer 235, poloxamer 237, poloxamer 238, poloxamer 282, poloxamer 284, poloxamer 288, poloxamer 304, poloxamer 331, poloxamer 333, poloxamer 334, poloxamer 335, poloxamer 338, poloxamer 401, poloxamer 402, poloxamer 403, poloxamer 407 or combination thereof.

### Claim 60 (depends on 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The process of any one of claims 42-59, wherein the non-cationic lipid is dioleoylphosphatidylethanolamine (DOPE).

### Claim 61 (depends on 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The process of any one of claims 42-59, wherein the process does not include mixing any cholesterol lipids.

### Claim 62 (depends on 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61)

The process of any one of claims 42-61, wherein the lipid nanoparticles have an encapsulation efficiency of at least 50%.

### Claim 63 (depends on 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61)

The process of claim 42-61, wherein the lipid nanoparticles have an encapsulation efficiency of between about 60% and 99%.

### Claim 64 (depends on 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)

The process of any one of claims 42-63, wherein the lipid nanoparticles have an average size of about 200 nm or less.

### Claim 65 (depends on 64)

The process of claim 64, wherein the lipid nanoparticles have an average size of about 150 nm or less, 140 nm or less, 130 nm or less, 120 nm or less, 110 nm or less, or about 100 nm or less.

### Claim 66 (depends on 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)

A composition comprising lipid nanoparticles encapsulating mRNA formed according to a process of any one of claims 42-63.
